PPD

SEPTEMBER 25, 2023

As the clinical trial landscape evolves, drug developers are faced with novel challenges and changes in study recruitment, trial size and structure, and more. The adoption of new innovations, strategies and technologies offers opportunities to address persistent challenges and develop suitable approaches for the future.

Drug Development 104

Drug Development Clinical Trials Drugs Trials 104

Drug Patent Watch

DECEMBER 12, 2024

This approach not only helps maintain market exclusivity but also ensures a steady revenue stream for pharmaceutical companies. In this comprehensive guide, we’ll explore the intricacies of identifying such drugs and leveraging them for successful in-licensing opportunities.

Licensing 96

Licensing Licensing Drugs Biosimilars 96

DrugBank

OCTOBER 4, 2024

Deal Structuring Deal structuring in pharmaceutical M&A requires a balance of financial, legal, and strategic considerations. Intellectual Property Valuation Valuing intellectual property (IP) assets is a critical component of pharmaceutical M&A, as these assets often represent a significant portion of a company's value.

Pharmaceuticals 98

Pharmaceuticals Pharmaceutical Companies Therapies Marketing 98

Drug Target Review

JULY 18, 2023

Artificial Intelligence (AI) is poised to transform the field of target discovery in drug development, offering immense potential to enhance efficacy, personalised medicine, and accelerate the development of innovative compounds. This means that we are not doing something right.

Drug Development 98

Drug Development Drugs Clinical Development Pharmaceutical Companies 98

SCIENMAG: Medicine & Health

OCTOBER 31, 2023

— A new drug developed by professors from the School of Pharmacy and Pharmaceutical Sciences at Binghamton University has received Food and Drug Administration (FDA) approval for the treatment of patients with Duchenne muscular dystrophy (DMD), a common genetic disease that mostly affects young boys.

FDA Approval 83

FDA Approval FDA Disease Pharmacy 83

Drug Target Review

OCTOBER 30, 2024

Imagine being able to create an in vitro replica of a diseased organ to study the molecular mechanism underlying the illness. Now take a step further: envision testing drugs in these organoids to identify the ones that can treat disease safely and effectively without needing to run expensive clinical trials first.

Treatment 105

Treatment Disease Clinical Trials Research 105

Drug Target Review

JANUARY 8, 2024

It is no mystery that as we age our health starts to deteriorate, and we become increasingly susceptible to diseases. Through years of scientific exploration and research, we now know there are several biological changes that make our bodies more susceptible to disease or injury, and we can target those with therapeutic interventions.

Science 145

Science Disease FDA Approval Clinical Trials 145

Conversations in Drug Development Trends

MAY 14, 2024

By: Amy Raymond, Derek Ansel, Nathan Chadwick, & Juliane Mills When choosing a CRO for a rare disease study, what truly sets them apart is their methodology: the CRO’s mindset, their approach to each unique study, and their agility in navigating the inherent complexities of rare disease research. Common goals empower change.

Disease 81

Disease Clinical Trials Trials Pharmaceutical Companies 81

Drug Patent Watch

AUGUST 21, 2024

The pharmaceutical industry has witnessed a significant surge in the availability of public disease and drug-related data, which has facilitated […] Source

Drug Development 59

Drug Development Drugs Pharmaceuticals Disease 59

LifeSciVC

JULY 17, 2024

By Mike Cloonan, Chief Executive Officer of Sionna Therapeutics, as part of the From The Trenches feature of LifeSciVC The drug development process in rare diseases is rife with challenges especially when companies target significant differentiation or first-in-class targets.

Clinical Research 74

Clinical Research Disease Research Clinical Trials 74

PPD

SEPTEMBER 16, 2024

The pharmaceutical industry is currently experiencing a significant transformation. The convergence of real-world data (RWD), technology and artificial intelligence (AI) is playing a vital role in accelerating drug development. AI is also proving useful in drug repurposing or indication selection.

Clinical Development 98

Clinical Development Clinical Trials Clinical Research Trials 98

DrugBank

AUGUST 20, 2024

The world of drug discovery is in a state of transformation, with advancements in biotechnology opening doors to new possibilities for targeting previously "undruggable" disease mechanisms. We also explore why some disease-associated targets remain elusive and how recent innovations are changing that narrative.

Therapies 98

Therapies Pharmaceuticals Disease Research 98

DrugBank

MAY 15, 2024

Today, we're able to identify and target specific molecules involved in disease processes—a method that's much more like using a sniper rifle than throwing darts blindfolded. Among these targets are proteins, receptors, and enzymes that are fundamental to disease mechanisms.

Small Molecule 98

Small Molecule Molecular Biology Drugs Disease 98

Advarra

AUGUST 16, 2022

A rare, or orphan, disease by definition affects a small percentage of the population — fewer than 200,000 people in the U.S. But the numbers add up, and taken together, rare diseases impact an estimated 30 million Americans. Since then, the FDA has significantly changed its approach to rare and orphan diseases.

Disease 52

Disease Clinical Trials FDA Approval FDA 52

Drug Target Review

SEPTEMBER 19, 2024

Could you give us an overview of IRLAB’s current drug development pipeline? Based on Nobel Prize-winning research, IRLAB has grown rapidly to become recognised and respected as a world-leader in understanding the complex neuropharmacology of CNS disorders, especially Parkinson’s disease (PD).

Disease 52

Disease Drugs Treatment Drug Development 52

Drug Target Review

MARCH 4, 2025

A personalised approach to obesity treatment Traditional obesity treatments have often followed a one-size-fits-all model, despite mounting evidence that obesity is not a singular disease but rather a collection of subtypes. This growing health challenge increases the risk of diabetes, heart disease, and other conditions.

Therapies 52

Therapies Treatment Clinical Trials Science 52

DrugBank

DECEMBER 18, 2024

A new shift is occurring in the pharmaceutical industry, leading to a rapidly expanding field known as digital therapeutics (DTx). These interventions target a broad spectrum of medical conditions, encompassing chronic diseases and even substance abuse. Healthcare providers also stand to gain significantly from DTx adoption.

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Treatment Therapies 52

Drug Target Review

DECEMBER 11, 2024

This shift in focus is especially critical in toxicology, where accurate target analysis plays a vital role in identifying toxic effects and ensuring patient safety, particularly as the field transitions from traditional drugs to the promising realm of biotherapeutics, especially for rare diseases.

International 52

International Laboratories Drugs Pharmacokinetics 52

Drug Target Review

NOVEMBER 29, 2023

We are truly pushing the boundaries of drug discovery with our unique patient-forward approach to target discovery. We focus on patients who are resilient to disease and conduct an unbiased search for protective autoantibodies in these patients that may underlie their resiliency. Sifis: Thank you, Michelle!

Engineering 111

Engineering Drug Development Disease Research 111

PPD

JUNE 7, 2023

Adults aren’t the only patients affected by the increasing prevalence of liver disease. The number of pediatric patients diagnosed with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is on the rise, yet there are currently no approved therapies to treat NAFLD and NASH in adult or pediatric populations.

Trials 98

Trials Clinical Trials Clinical Research Disease 98

Drug Target Review

FEBRUARY 1, 2024

What challenges has the industry faced in developing and commercialising treatments for neurological diseases, including rare diseases? But commitment to neuroscience drug development is critically important given the significant unmet medical needs and the ways in which patients, caregivers, and families suffer.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

Drug Target Review

SEPTEMBER 19, 2023

The chips can be modelled with primary cells, IPS derived stem cells or patient derived cells and potentiates to unlock molecular mechanisms that drive the disease pathophysiology, holding a greater promise. The first successful chip adaptation to a lung model was first described in 2010 by Donald Ingber, a bioengineer at Wyss institute.

Animal Testing 98

Animal Testing Clinical Trials Pharmaceutical Companies FDA 98

Drug Target Review

JULY 4, 2023

In practice, some patients may be left managing a syndrome associated with the therapy along with the disease. 3D rendering of Antibody Drug Conjugate Molecules. Antibody drug conjugated with cytotoxic payload. antibody linked to a biologically active cytotoxic (anticancer) payload or drug 3d rendering.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

DrugBank

JANUARY 22, 2025

Environmental Impacts of Traditional Pharmaceutical Production Traditional pharmaceutical manufacturing is complex, with each phase contributing to environmental degradation. The extraction and synthesis of active pharmaceutical ingredients (API) utilize vast amounts of water and energy.

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Production Government 52

LifeSciVC

AUGUST 5, 2024

We are constantly reminded how we are in the midst of an artificial intelligence revolution of the drug development process which promises to completely transform how we develop drugs with increases in productivity of an order of magnitude or more.

Molecular Biology 95

Molecular Biology Production Drug Development Small Molecule 95

Drug Target Review

MARCH 17, 2025

Advancing drug candidates across key therapeutic areas Dr John Donello brings over 25 years of experience in pharmaceutical drug discovery, development and collaborations. Now in Phase II development at Gate for depression and other synaptopathies, zelquistinel represents a key part of his current work.

Treatment 52

Treatment Licensing Licensing Science 52

Alta Sciences

MARCH 27, 2024

Up Close and Personal With Eryn Corriveau, MSc, Senior Director, Drug Development and Regulatory Strategy nbartlett Wed, 03/27/2024 - 20:21 Here at Altasciences, Eryn is responsible for guiding regulatory strategies , conducting gap analyses, and leading interactions with regulatory agencies dur ing early drug development.

Drug Development 52

Drug Development Medical Schools Pharma Companies Drugs 52

FDA Law Blog: Biosimilars

JUNE 27, 2023

Amongst his accomplishments, Law360 considered the role James has played in leveraging little-used pathways to FDA approval for often first-ever drugs to treat rare diseases (e.g., Duchenne, Friederichs’s Ataxia, Sickle Cell Disease, Chagas, ALS).

Science 81

Science FDA Approval FDA Drug Development 81

DrugBank

JUNE 27, 2024

Drug repurposing is an approach that, while not new, has become popular in the last decade. Additionally, integrating diverse data types is a high demand task , and obtaining generic active ingredients can be challenging, especially if the drug is no longer commercially available.

Drugs 98

Drugs Pharma Companies Clinical Trials Computational Chemistry 98

The Pharma Data

AUGUST 5, 2021

and described today in eLife, may help expedite the process by helping scientists find promising, existing drugs that might be repurposed for these diseases. And they identified over 1,300 potential anti-COVID-19 drugs, including some that are already safely used to treat a number of other conditions.

Disease 52

Disease Drugs Laboratories Engineering 52

Drug Target Review

DECEMBER 16, 2024

Dr Pooja Hingorani, Senior Medical Director of Oncology Early Development at AbbVie , shares her journey in STEM, from her early days in New Delhi to her impactful career in oncology research and drug development. Opportunities in clinical research and drug development were not always easy to come by.

Medical Schools 52

Medical Schools Clinical Research Drug Development Trials 52

Broad Institute

NOVEMBER 2, 2023

Combining Broad’s expertise in cancer biology and state-of-the-art drug discovery methods with Bayer’s expertise in drug development greatly increases our power to bring transformative medicines to cancer patients.” “We

Therapies 105

Therapies Research Small Molecule Clinical Trials 105

Conversations in Drug Development Trends

MAY 14, 2024

By: Amy Raymond, Derek Ansel, Nathan Chadwick, & Juliane Mills When choosing a CRO for a rare disease study, what truly sets them apart is their methodology: the CRO’s mindset, their approach to each unique study, and their agility in navigating the inherent complexities of rare disease research. Common goals empower change.

Disease 52

Disease Clinical Trials Trials Pharmaceutical Companies 52

DrugBank

APRIL 12, 2024

Over the past decade, the drug discovery landscape has been revolutionized by the adoption of artificial intelligence (AI) and machine learning (ML), witnessing early adopters leapfrog into pioneering technologies aimed at streamlining the drug development process and curtailing associated costs.

Drugs 98

Drugs Clinical Trials Pharmaceutical Companies Pharmaceuticals 98

Drug Target Review

NOVEMBER 25, 2024

I went on to complete my MBA and PhD at The Institute of Cancer Research (ICR) in drug development. At this point, I knew that I wanted to join the biotech and pharmaceutical industry, so I moved to a small biotech company in London, where I spent three to four years learning the fundamentals of the biotech industry.

Treatment 52

Treatment Small Molecule Clinical Trials Trials 52

The Pharma Data

NOVEMBER 9, 2020

Löbenberg is a director of XPhyto and is the founder and director of the Drug Development and Innovation Centre, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada. About XPhyto Therapeutics Corp. XPhyto Therapeutics Corp.

Drug Development 40

Drug Development Drugs Clinical Pharmacology Pharmaceuticals 40

DrugBank

JANUARY 15, 2025

Introduction Orphan drugs, specifically developed to treat rare diseases, represent a unique and challenging pharmaceutical industry segment. However, their significance in addressing the unmet medical needs of patients with rare diseases must be considered.

Drugs 52

Drugs Drug Development Clinical Trials Therapies 52